filmov
tv
Zelluna Immunotherapy
Показать описание
Anders Holm, Ph.D., COO
Oslo, Norway
(Private)
Zelluna Immunotherapy is developing innovative T-cell receptor (TCR) based cancer therapies for patients with a high unmet medical need. The company’s core asset and unique competitive advantage is a large portfolio of TCRs isolated from long term surviving patients from peptide vaccine trials. Our TCRs are directed against epitopes from the known tumor associated antigens TGFβRII, hTERT and K-Ras and have the potential to be used in the treatment of a broad range of solid tumors. Zelluna has a long-term collaborative research and development agreement with the Department of Cell Therapy at the Oslo University Hospital and is in the process of setting up cell manufacturing capabilities in collaboration with MaSThercell. Zelluna aims to start its first clinical trial in 2019-2020.
Oslo, Norway
(Private)
Zelluna Immunotherapy is developing innovative T-cell receptor (TCR) based cancer therapies for patients with a high unmet medical need. The company’s core asset and unique competitive advantage is a large portfolio of TCRs isolated from long term surviving patients from peptide vaccine trials. Our TCRs are directed against epitopes from the known tumor associated antigens TGFβRII, hTERT and K-Ras and have the potential to be used in the treatment of a broad range of solid tumors. Zelluna has a long-term collaborative research and development agreement with the Department of Cell Therapy at the Oslo University Hospital and is in the process of setting up cell manufacturing capabilities in collaboration with MaSThercell. Zelluna aims to start its first clinical trial in 2019-2020.
0:11:15
0:10:27
0:13:21
0:03:38
0:04:52
0:08:20
0:46:26
0:04:19
0:15:06
0:14:33
0:55:51
0:04:42
0:01:15
0:02:38
1:16:08
0:29:33
0:02:46
0:01:28
0:02:59
0:02:58
0:02:02
0:02:47
0:55:55
0:02:43